Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

17 trials with published results (17%)

Research Maturity

51 completed trials (52% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.1%

6 terminated out of 99 trials

Success Rate

89.5%

+2.9% vs benchmark

Late-Stage Pipeline

13%

13 trials in Phase 3/4

Results Transparency

33%

17 of 51 completed with results

Key Signals

17 with results89% success

Data Visualizations

Phase Distribution

68Total
Not Applicable (35)
Early P 1 (3)
P 1 (4)
P 2 (13)
P 3 (6)
P 4 (7)

Trial Status

Completed51
Recruiting15
Unknown10
Terminated6
Active Not Recruiting6
Withdrawn6

Trial Success Rate

89.5%

Benchmark: 86.5%

Based on 51 completed trials

Clinical Trials (99)

Showing 20 of 20 trials
NCT07714694Not ApplicableRecruiting

Consumer Evaluation of an Investigational Intermittent Catheter

NCT07668063Phase 1Not Yet RecruitingPrimary

Device for Bladder Control for Men With SCI

NCT05462561Not ApplicableSuspendedPrimary

Vascularized Composite Bladder Allograft Transplantation

NCT06163469Not ApplicableRecruitingPrimary

Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life

NCT04936217Completed

Efficacy and Safety of a Continent Cutaneous Urinary Diversion in Spinal Cord Injury Patients

NCT04924569Active Not RecruitingPrimary

Continence Care Registry

NCT04791579Phase 2RecruitingPrimary

Antibiotic Prophylaxis for Neurogenic Bladder Botox

NCT04626167Early Phase 1Recruiting

Concomitant Renal and Urinary Bladder Allograft Transplantation

NCT07505940Not ApplicableNot Yet RecruitingPrimary

Bilateral Comparison of Unilateral Sacral Neuromodulation Test Stimulation in the Treatment of Neurogenic Bladder

NCT06072703Not ApplicableRecruitingPrimary

Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS

NCT06588010Phase 3RecruitingPrimary

Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder

NCT07390591Recruiting

Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms

NCT07387315Phase 4Not Yet Recruiting

A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections

NCT04248322Active Not RecruitingPrimary

Qualitative Assessment of the Impact of TTNS on QOL and Participation

NCT07308808Early Phase 1Recruiting

Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation

NCT01388413Phase 4CompletedPrimary

Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder

NCT04187027Not ApplicableActive Not RecruitingPrimary

Efficacy Of Pulsed Electromagnetic Field Therapy On Neurogenic Bladder in Children With Myelomeningocele

NCT05726786Phase 3Recruiting

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)

NCT04323735Phase 2RecruitingPrimary

Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters

NCT05230511Phase 2Recruiting

Intravesical LGG VS Saline Bladder Wash RCT

Scroll to load more

Research Network

Activity Timeline